Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2011 2
2012 3
2013 3
2014 3
2015 2
2016 4
2017 2
2018 4
2020 6
2021 4
2022 10
2023 7
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

47 results

Results by year

Filters applied: . Clear all
Page 1
Activated SUMOylation restricts MHC class I antigen presentation to confer immune evasion in cancer.
Demel UM, Böger M, Yousefian S, Grunert C, Zhang L, Hotz PW, Gottschlich A, Köse H, Isaakidis K, Vonficht D, Grünschläger F, Rohleder E, Wagner K, Dönig J, Igl V, Brzezicha B, Baumgartner F, Habringer S, Löber J, Chapuy B, Weidinger C, Kobold S, Haas S, Busse AB, Müller S, Wirth M, Schick M, Keller U. Demel UM, et al. Among authors: wirth m. J Clin Invest. 2022 May 2;132(9):e152383. doi: 10.1172/JCI152383. J Clin Invest. 2022. PMID: 35499080 Free PMC article.
SUMOylation inhibition overcomes proteasome inhibitor resistance in multiple myeloma.
Heynen GJJE, Baumgartner F, Heider M, Patra U, Holz M, Braune J, Kaiser M, Schäffer I, Bamopoulos SA, Ramberger E, Murgai A, Ng YLD, Demel UM, Laue D, Liebig S, Krüger J, Janz M, Nogai A, Schick M, Mertins P, Müller S, Bassermann F, Krönke J, Keller U, Wirth M. Heynen GJJE, et al. Among authors: wirth m. Blood Adv. 2023 Feb 28;7(4):469-481. doi: 10.1182/bloodadvances.2022007875. Blood Adv. 2023. PMID: 35917568 Free PMC article.
Small-molecule SUMO inhibition for biomarker-informed B-cell lymphoma therapy.
Demel UM, Wirth M, Yousefian S, Zhang L, Isaakidis K, Dönig J, Böger M, Singh N, Köse H, Haas S, Müller S, Schick M, Keller U. Demel UM, et al. Among authors: wirth m. Haematologica. 2023 Feb 1;108(2):555-567. doi: 10.3324/haematol.2022.280995. Haematologica. 2023. PMID: 36134453 Free PMC article.
SUMO pathway inhibition targets an aggressive pancreatic cancer subtype.
Biederstädt A, Hassan Z, Schneeweis C, Schick M, Schneider L, Muckenhuber A, Hong Y, Siegers G, Nilsson L, Wirth M, Dantes Z, Steiger K, Schunck K, Langston S, Lenhof HP, Coluccio A, Orben F, Slawska J, Scherger A, Saur D, Müller S, Rad R, Weichert W, Nilsson J, Reichert M, Schneider G, Keller U. Biederstädt A, et al. Among authors: wirth m. Gut. 2020 Aug;69(8):1472-1482. doi: 10.1136/gutjnl-2018-317856. Epub 2020 Jan 30. Gut. 2020. PMID: 32001555 Free PMC article.
HDAC2 Facilitates Pancreatic Cancer Metastasis.
Krauß L, Urban BC, Hastreiter S, Schneider C, Wenzel P, Hassan Z, Wirth M, Lankes K, Terrasi A, Klement C, Cernilogar FM, Öllinger R, de Andrade Krätzig N, Engleitner T, Schmid RM, Steiger K, Rad R, Krämer OH, Reichert M, Schotta G, Saur D, Schneider G. Krauß L, et al. Among authors: wirth m. Cancer Res. 2022 Feb 15;82(4):695-707. doi: 10.1158/0008-5472.CAN-20-3209. Cancer Res. 2022. PMID: 34903606 Free PMC article.
Epigenetic drug screening defines a PRMT5 inhibitor-sensitive pancreatic cancer subtype.
Orben F, Lankes K, Schneeweis C, Hassan Z, Jakubowsky H, Krauß L, Boniolo F, Schneider C, Schäfer A, Murr J, Schlag C, Kong B, Öllinger R, Wang C, Beyer G, Mahajan UM, Xue Y, Mayerle J, Schmid RM, Kuster B, Rad R, Braun CJ, Wirth M, Reichert M, Saur D, Schneider G. Orben F, et al. Among authors: wirth m. JCI Insight. 2022 May 23;7(10):e151353. doi: 10.1172/jci.insight.151353. JCI Insight. 2022. PMID: 35439169 Free PMC article.
The OTUD6B-LIN28B-MYC axis determines the proliferative state in multiple myeloma.
Paulmann C, Spallek R, Karpiuk O, Heider M, Schäffer I, Zecha J, Klaeger S, Walzik M, Öllinger R, Engleitner T, Wirth M, Keller U, Krönke J, Rudelius M, Kossatz S, Rad R, Kuster B, Bassermann F. Paulmann C, et al. Among authors: wirth m. EMBO J. 2022 Oct 17;41(20):e110871. doi: 10.15252/embj.2022110871. Epub 2022 Sep 5. EMBO J. 2022. PMID: 36059274 Free PMC article.
AP1/Fra1 confers resistance to MAPK cascade inhibition in pancreatic cancer.
Schneeweis C, Diersch S, Hassan Z, Krauß L, Schneider C, Lucarelli D, Falcomatà C, Steiger K, Öllinger R, Krämer OH, Arlt A, Grade M, Schmidt-Supprian M, Hessmann E, Wirth M, Rad R, Reichert M, Saur D, Schneider G. Schneeweis C, et al. Among authors: wirth m. Cell Mol Life Sci. 2022 Dec 19;80(1):12. doi: 10.1007/s00018-022-04638-y. Cell Mol Life Sci. 2022. PMID: 36534167 Free PMC article.
Survivin and YM155: how faithful is the liaison?
Rauch A, Hennig D, Schäfer C, Wirth M, Marx C, Heinzel T, Schneider G, Krämer OH. Rauch A, et al. Among authors: wirth m. Biochim Biophys Acta. 2014 Apr;1845(2):202-20. doi: 10.1016/j.bbcan.2014.01.003. Epub 2014 Jan 16. Biochim Biophys Acta. 2014. PMID: 24440709 Review.
Concepts to Target MYC in Pancreatic Cancer.
Wirth M, Mahboobi S, Krämer OH, Schneider G. Wirth M, et al. Mol Cancer Ther. 2016 Aug;15(8):1792-8. doi: 10.1158/1535-7163.MCT-16-0050. Epub 2016 Jul 12. Mol Cancer Ther. 2016. PMID: 27406986 Review.
47 results